Hikal Q4 Review - Strong Growth Across Segments: ICICI Direct
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICICI Direct Report
Hikal Ltd.'s Q4 revenue grew a robust 40.5% YoY to Rs 533 crore tracking strong growth across both segments.
Pharma posted 31.5% YoY growth to Rs 298 crore whereas crop protection grew 53.8% YoY to Rs 235 crore.
Ebitda margin expanded 188 basis points YoY, 81 basis points QoQ to 20.5% amid lower staff expenses stemming from better operational leverage.
Subsequently, Ebitda grew 54.7% YoY to Rs 109 crore. Profit after tax more than doubled to Rs 4 crore.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.